Artelon

About Artelon

Artelon is a medical device company focused on developing solutions for soft tissue reconstruction in the orthopedic and podiatric surgery markets. The company provides bio-textile implants that augment and reinforce the surgical repair of tendons and ligaments.

The foundational technology was conceived in the 1990s by Dr. Lars Peterson, a renowned orthopedic surgeon, who sought a more reliable synthetic material for ligament and tendon reconstruction after observing failures in existing devices. This led to the creation of Artelon's Dynamic Matrix, a proprietary polymeric bio-textile. The initial Swedish company operated for about a decade before its assets were acquired out of bankruptcy by U.S. investors in 2014. In 2017, Aaron C. Smith, a biomedical engineer with extensive experience in the orthopedic sector at companies like Wright Medical and as a co-founder of Amniox Medical, was appointed CEO to pivot and commercialize the technology. Under his leadership, the company focused its strategy on the significant, yet underserved, market for ankle instability. This strategic shift proved successful, leading to a $20 million Series B funding round in May 2023, led by Vensana Capital, to fuel commercial growth and clinical research. In a key milestone, Stryker, a global medical technology leader, announced a definitive agreement to acquire Artelon on June 3, 2024, and completed the acquisition on July 15, 2024.

Artelon's business model centers on the design, manufacturing, and sale of its soft tissue reinforcement products to surgeons and healthcare facilities. The company targets the foot and ankle and sports medicine segments, addressing conditions like chronic ankle instability, which is a common consequence of ankle sprains. The products are sold as single-use, sterile kits that include implants and instrumentation, designed to fit seamlessly into surgical workflows. The company’s revenue is generated from the sale of these surgical kits.

The core of Artelon's offering is its Dynamic Matrix® technology, a bio-scaffold made from a patented co-polymer of polycaprolactone and polyurethane-urea. This material is engineered to mimic the strength and elasticity of natural ligaments, allowing it to stretch and rebound with the joint's movement. Products like the FLEXBAND® family are designed to reinforce a surgeon's primary repair, providing mechanical support during the critical healing phase. A key benefit is that the implant integrates with the patient's own tissue, acting as a scaffold for regeneration before slowly degrading over a period of four to six years, by which point it is replaced by organized collagen. This approach aims to enable faster recovery, restore stable motion, and improve long-term patient outcomes compared to traditional surgical procedures. The product portfolio includes various configurations like FlexBand® SOLO, MULTI, and Twist to address different surgical needs from single to complex multi-ligament reconstructions.